Online citations, reference lists, and bibliographies.
← Back to Search

PEGylated Polycyanoacrylate Nanoparticles As Tumor Necrosis Factor-α Carriers

Y. Li, Yuan-ying Pei, Zhaohui Zhou, Xian-ying Zhang, Z. Gu, J. Ding, J. Zhou, Xiu-Jian Gao
Published 2001 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract The aim of this study was to find an effective carrier for recombinant human tumor necrosis factor-α (rHuTNF-α). The influence of solvent systems containing poly(methoxy-polyethyleneglycol cyanoacrylate-co- n -hexadecyl cyanoacrylate) (PEGylated PHDCA) on the biological activity of rHuTNF-α was investigated. The PEGylated PHDCA nanoparticles loading rHuTNF-α were prepared with the double emulsion method. The influence of main experimental factors on the entrapment efficiency was evaluated by the Uniform Design. The physicochemical characteristics and in vitro release of rHuTNF-α from the nanoparticles were determined. The results showed that serum albumin such as human serum albumin (HSA) or bovine serum albumin (BSA) could play a protective action on rHuTNF-α in the preparation process. At ≥2.0% (w/v) HSA concentration, more than 85% of rHuTNF-α activity remained and the role of HSA was not affected by copolymer concentrations from 0.5 to 3.0% (w/v). The entrapment efficiency of the nanoparticles was about 60% and the nanoparticle size was about 150 nm. The nanoparticles were spherical in shape and uniform with the value of the zeta potential about −9 mV. The rHuTNF-α release from the nanoparticle showed an initial burst and then continued in a sustained fashion. The results showed that the PEGylated PHDCA nanoparticles could be an effective carrier for rHuTNF-α.
This paper references
10.1097/00002371-199501000-00003
Hemodynamic Evaluation of Recombinant Human Tumor Necrosis Factor (TNF)-α, TNF‐SAM2 and Liposomal TNF‐SAM2 in an Anesthetized Dog Model
R. Lodato (1995)
10.1248/BPB.23.318
Positively charged liposomes containing tumor necrosis factor in solid tumors.
K. Yasui (2000)
Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
A. Asher (1987)
10.1016/S0939-6411(97)00056-8
Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres
M. D. Blanco (1997)
10.3109/02652049809006831
Polymer-coated long-circulating microparticulate pharmaceuticals.
V. Torchilin (1998)
10.1016/S0024-3205(97)00539-0
Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles.
M. Peracchia (1997)
10.20772/CANCERSCI1985.78.2_193
The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor.
M. Nobuhara (1987)
10.1016/0277-5379(89)90034-5
Phase I study of intratumoral application of recombinant human tumor necrosis factor.
M. Pfreundschuh (1989)
10.1016/S0142-9612(99)00021-6
Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles.
M. Peracchia (1999)
10.3109/10837459809028504
Stabilization of dichloromethane-induced protein denaturation during microencapsulation.
R. Raghuvanshi (1998)
10.1016/S0378-5173(96)04779-5
Lipid nanoparticles for delivering antitumor drugs
N. Hodoshima (1997)
10.1016/S0378-5173(99)00092-7
A genetically modified recombinant tumor necrosis factor-alpha conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains.
M. Savva (1999)
10.1016/S0304-3835(00)00410-9
Potential usage of thermosensitive liposomes for site-specific delivery of cytokines.
Y. Yuyama (2000)
Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats.
R. Debs (1990)
10.1038/NBT0890-755
Controlled Release of Interleukin-2 from Biodegradable Microspheres
M. Hora (1990)
10.1002/(SICI)1097-0215(19980911)77:6<901::AID-IJC17>3.0.CO;2-3
Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats
Alexander H. van der Veen (1998)
10.1002/(SICI)1097-4636(199810)42:1<45::AID-JBM7>3.0.CO;2-O
Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization.
P. Quellec (1998)
Drug-loaded nanoparticles – preparation methods and drug targeting issues
E. Alleman (1993)
10.1016/0168-3659(90)90149-N
Albumin microspheres and microcapsules: Methodology of manufacturing techniques
R. Arshady (1990)
10.1073/PNAS.72.9.3666
An endotoxin-induced serum factor that causes necrosis of tumors.
E. Carswell (1975)
Preparation and characterization of liposomal-lipophilic tumor necrosis factor.
T. Utsumi (1991)
10.1126/SCIENCE.8128245
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
10.1016/S0378-5173(97)00416-X
Stealth® liposomal tumor necrosis factor-α in solid tumor treatment
Alexander H. van der Veen (1998)
10.1016/0168-3659(94)00106-5
Long-acting delivery system of interferon: IFN minipellet
K. Fujioka (1995)
10.1200/JCO.1992.10.1.52
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
D. Liénard (1992)
10.1016/S0378-5173(97)00306-2
Selection of the solvent system for the preparation of poly(d,l-lactic-co-glycolic acid) microspheres containing tumor necrosis factor-alpha (TNF-α)
M. Iwata (1998)
10.1097/00002371-199705000-00003
Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice.
E. Kedar (1997)
10.1073/PNAS.85.18.6949
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
A. Gabizon (1988)



This paper is referenced by
10.1002/0471732877.EMD274
Drug Delivery Systems
D. Paolino (2006)
10.2174/1574889808666131128105141
Patents on brain permeable nanoparticles.
Monica Gulati (2013)
10.1080/10611860701603372
Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery
C. Vauthier (2007)
10.1016/j.biomaterials.2011.07.032
Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
H. Wang (2011)
10.1016/S0169-409X(02)00044-3
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
10.1111/j.1751-1097.2008.00481.x
Photoinduced Nitric Oxide and Singlet Oxygen Release from ZnPC Liposome Vehicle Associated with the Nitrosyl Ruthenium Complex: Synergistic Effects in Photodynamic Therapy Application
D. S. Maranho (2009)
10.1016/j.pneurobio.2008.12.002
Delivery of peptide and protein drugs over the blood–brain barrier
I. Brasnjevic (2009)
10.1007/s10856-007-3358-1
Key parameters affecting the initial leaky effect of hemoglobin-loaded nanoparticles as blood substitutes
X. Zhang (2008)
10.1002/JPS.20491
Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Bin Bin Shi (2006)
10.1016/J.EJPB.2004.10.006
Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.
U. Bilati (2005)
10.1023/A:1025575730542
Plug-in Spectrometry with Optical Fibers as a Novel Analytical Tool for Nanoparticles Technology: Application to the Investigation of the Emulsion Polymerization of the Alkylcyanoacrylate
C. Chauvierre (2003)
10.3109/03639045.2013.861480
Antitumor activity of TNF-α after intratumoral injection using an in situ thermosensitive hydrogel
Yourui Xu (2015)
10.3109/02652048.2011.635426
Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation
Meltem Cetin (2012)
Karakteristikdan AplikasiPartikelNano dalam Manipulasi Hormon Reproduksi pada Ternak
Aji Pamungkas (2015)
10.1007/978-3-319-41129-3_2
Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery Applications
Saurabh Bhatia (2016)
10.1007/978-3-319-77119-9_3
Classification of Green Nanoparticles
Beenish Zia Butt (2018)
10.1016/J.BIOMATERIALS.2006.12.016
In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease.
P. Zhang (2007)
Poly(alkycyanoacrylate) nanoparticlesforenhanced deliveryoftherapeutics-isthere realpotential?
Anja Graf (2009)
10.2174/1389201015666140508122558
Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges.
Meeta Gidwani (2014)
10.1201/9780849374555-11
Polymeric Nanoparticles for Oral Drug Delivery
V. Kumar (2006)
10.1163/156855206775123494
Nanoparticles for cancer therapy and diagnosis
Y. Fukumori (2006)
10.4161/tisb.29528
Barriers to drug delivery in solid tumors
Shravan Kumar Sriraman (2014)
10.4015/S101623720400030X
POTENTIAL USAGE OF LIPOSOME-ENCAPSULATED PHOSPHOR FOR IN VIVO IMAGING OF TISSUE OXYGENATION
L. Lo (2004)
10.1201/9780203913338-26
From Polymer Chemistry and Physicochemistry to Nanoparticulate Drug Carrier Design and Applications
C. Vauthier (2003)
10.1016/j.bbr.2006.06.001
Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice
Y. Xie (2006)
10.7897/2230-8407.04408
NANOPARTICLE: AN OVERVIEW OF PREPARATION, CHARACTERIZATION AND APPLICATION
K. Ranjit (2016)
10.2217/17435889.1.4.481
Nanocarriers for overcoming multidrug resistance in cancers.
R. Banerjee (2006)
Designing oligoarginine-associated PECA nanoparticles for enhanced cellular uptake
J. Z. S. Chiu (2014)
10.1016/B978-0-12-384964-9.00011-6
Parenteral Delivery of Peptides and Proteins
H. Agrawal (2011)
10.1002/3527600035.BPOL9021
Biodegradation of Poly(alkylcyanoacrylates)
C. Vauthier (2002)
10.1016/j.actbio.2019.02.016
Advances in immunotherapy delivery from implantable and injectable biomaterials.
David G. Leach (2019)
10.1002/APP.28940
Preparation and in vitro release of D,L-tetrahydropalmatine-loaded graft copolymer nanoparticles
Yinglei Zhai (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar